Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Unternehmen & Branche
| Name | BIOMARIN PHARMACEUTICAL INC |
|---|---|
| Ticker | BMRN |
| CIK | 0001048477 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 09061G101 |
|---|---|
| ISIN | US09061G1013 |
| Typ | Common Stock |
| Marktkapitalisierung | 10,61 Mrd. USD |
| Beta | 0,29 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 3,221,253,000 | 348,901,000 | 1.80 | 7,594,022,000 | 6,086,999,000 |
| 2025-09-30 | 10-Q | 776,133,000 | -30,744,000 | -0.16 | 7,614,868,000 | 6,056,711,000 |
| 2025-06-30 | 10-Q | 825,410,000 | 240,532,000 | 1.23 | 7,456,341,000 | 6,027,113,000 |
| 2025-03-31 | 10-Q | 745,145,000 | 185,686,000 | 0.95 | 7,147,007,000 | 5,793,459,000 |
| 2024-12-31 | 10-K | 2,853,915,000 | 426,859,000 | 2.21 | 6,988,940,000 | 5,657,990,000 |
| 2024-09-30 | 10-Q | 745,740,000 | 106,080,000 | 0.55 | 6,851,195,000 | 5,413,396,000 |
| 2024-06-30 | 10-Q | 712,029,000 | 107,174,000 | 0.55 | 7,067,121,000 | 5,286,299,000 |
| 2024-03-31 | 10-Q | 648,833,000 | 88,662,000 | 0.46 | 6,872,673,000 | 5,073,816,000 |
| 2023-12-31 | 10-K | 2,419,226,000 | 167,645,000 | 0.87 | 6,841,603,000 | 4,951,549,000 |
| 2023-09-30 | 10-Q | 581,329,000 | 40,378,000 | 0.21 | 6,758,163,000 | 4,896,897,000 |
| 2023-06-30 | 10-Q | 595,275,000 | 56,040,000 | 0.29 | 6,563,172,000 | 4,782,827,000 |
| 2023-03-31 | 10-Q | 596,415,000 | 50,852,000 | 0.27 | 6,433,695,000 | 4,659,043,000 |
| 2022-12-31 | 10-K | 2,096,039,000 | 141,561,000 | 0.75 | 6,375,074,000 | 4,603,156,000 |
| 2022-09-30 | 10-Q | 505,344,000 | -6,652,000 | -0.04 | 6,264,040,000 | 4,568,514,000 |
| 2022-06-30 | 10-Q | 533,798,000 | 27,664,000 | 0.15 | 6,145,841,000 | 4,499,737,000 |
| 2022-03-31 | 10-Q | 519,359,000 | 120,798,000 | 0.63 | 6,062,707,000 | 4,386,244,000 |
| 2021-12-31 | 10-K | 1,846,275,000 | -64,080,000 | -0.35 | 6,004,772,000 | 4,265,669,000 |
| 2021-09-30 | 10-Q | 408,742,000 | -36,494,000 | -0.20 | 5,977,475,000 | 4,261,078,000 |
| 2021-06-30 | 10-Q | 501,693,000 | 12,941,000 | 0.07 | 5,898,496,000 | 4,236,500,000 |
| 2021-03-31 | 10-Q | 486,030,000 | 17,371,000 | 0.09 | 5,805,053,000 | 4,162,010,000 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 61,098,108 | 0 | 61,098,108 | 1,177,395,797 | Neu | +100,0% | |
| VANGUARD GROUP INC | 18,127,847 | 0 | 18,127,847 | 1,077,337,946 | Neu | +100,0% | |
| PRIMECAP MANAGEMENT CO/CA/ | 14,549,314 | 0 | 14,549,314 | 864,665,732 | Neu | +100,0% | |
| STATE STREET CORP | 20,414,218 | 0 | 20,414,218 | 459,461,028 | Neu | +100,0% | |
| NORGES BANK | 7,531,080 | 0 | 7,531,080 | 447,572,084 | Neu | +100,0% | |
| AQR CAPITAL MANAGEMENT LLC | 6,686,916 | 0 | 6,686,916 | 395,196,725 | Neu | +100,0% | |
| VIKING GLOBAL INVESTORS LP | 6,036,936 | 0 | 6,036,936 | 358,775,106 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 3,674,089 | 0 | 3,674,089 | 218,394,606 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 20,715,616 | 0 | 20,715,616 | 207,938,242 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 3,321,754 | 0 | 3,321,754 | 197,404,798 | Neu | +100,0% | |
| Vestal Point Capital, LP | 3,000,000 | 0 | 3,000,000 | 178,290,000 | Neu | +100,0% | |
| Capital Research Global Investors | 2,547,287 | 0 | 2,547,287 | 151,385,266 | Neu | +100,0% | |
| UBS Group AG | 2,567,721 | 0 | 2,567,721 | 144,004,260 | Neu | +100,0% | |
| MORGAN STANLEY | 3,387,620 | 0 | 3,387,620 | 138,644,244 | Neu | +100,0% | |
| Deep Track Capital, LP | 2,300,000 | 0 | 2,300,000 | 136,689,000 | Neu | +100,0% | |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 116,500,000 | 0 | 116,500,000 | 112,244,512 | Neu | +100,0% | |
| FMR LLC | 1,837,071 | 0 | 1,837,071 | 109,177,147 | Neu | +100,0% | |
| Squarepoint Ops LLC | 1,835,244 | 0 | 1,835,244 | 109,068,551 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 1,676,191 | 0 | 1,676,191 | 99,616,031 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 1,547,965 | 0 | 1,547,965 | 91,995,561 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,473,610 | 0 | 1,473,610 | 87,576,642 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 1,504,198 | 0 | 1,504,198 | 87,113,838 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 1,436,639 | 0 | 1,436,639 | 85,379,456 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,423,712 | 0 | 1,423,712 | 84,611,204 | Neu | +100,0% | |
| Assenagon Asset Management S.A. | 1,419,067 | 0 | 1,419,067 | 84,335,152 | Neu | +100,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 1,324,971 | 0 | 1,324,971 | 78,743,027 | Neu | +100,0% | |
| Soleus Capital Management, L.P. | 1,320,000 | 0 | 1,320,000 | 78,447,600 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 1,283,622 | 0 | 1,283,622 | 76,426,918 | Neu | +100,0% | |
| D. E. Shaw & Co., Inc. | 1,064,029 | 0 | 1,064,029 | 63,235,243 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 7,703,512 | 0 | 7,703,512 | 57,929,042 | Neu | +100,0% | |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 1,111,698 | 0 | 1,111,698 | 57,708,242 | Neu | +100,0% | |
| Brandywine Global Investment Management, LLC | 945,847 | 0 | 945,847 | 56,211,687 | Neu | +100,0% | |
| Man Group plc | 36,137,495 | 0 | 36,137,495 | 55,873,328 | Neu | +100,0% | |
| River Road Asset Management, LLC | 906,366 | 0 | 906,366 | 53,865,331 | Neu | +100,0% | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 849,744 | 0 | 849,744 | 50,500,286 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 3,451,095 | 0 | 3,451,095 | 49,219,785 | Neu | +100,0% | |
| Swedbank AB | 796,737 | 0 | 796,737 | 47,350,080 | Neu | +100,0% | |
| Robeco Institutional Asset Management B.V. | 766,432 | 0 | 766,432 | 45,549,053 | Neu | +100,0% | |
| Palo Alto Investors LP | 746,256 | 0 | 746,256 | 44,349,994 | Neu | +100,0% | |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | 713,979 | 0 | 713,979 | 42,431,772 | Neu | +100,0% | |
| LOOMIS SAYLES & CO L P | 711,771 | 0 | 711,771 | 42,300,550 | Neu | +100,0% | |
| DEUTSCHE BANK AG\ | 687,658 | 0 | 687,658 | 40,867,513 | Neu | +100,0% | |
| OAKTREE CAPITAL MANAGEMENT LP | 42,118,000 | 0 | 42,118,000 | 40,450,127 | Neu | +100,0% | |
| Hudson Bay Capital Management LP | 670,002 | 0 | 670,002 | 39,818,219 | Neu | +100,0% | |
| JPMORGAN CHASE & CO | 9,416,005 | 0 | 9,416,005 | 39,447,793 | Neu | +100,0% | |
| Novo Holdings A/S | 660,000 | 0 | 660,000 | 39,223,800 | Neu | +100,0% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 638,725 | 0 | 638,725 | 37,959,428 | Neu | +100,0% | |
| Legal & General Group Plc | 603,581 | 0 | 603,581 | 35,870,818 | Neu | +100,0% | |
| CANADA PENSION PLAN INVESTMENT BOARD | 584,300 | 0 | 584,300 | 34,724,949 | Neu | +100,0% | |
| CAPSTONE INVESTMENT ADVISORS, LLC | 35,010,000 | 0 | 35,010,000 | 34,208,300 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-11 | Guyer Charles Greg | Officer, EVP, Chief Technical Officer | Open Market Sale | -16,486 | 60.46 | -996,743.56 | -160,7% | |
| 2026-02-26 | Friberg Gregory R | Officer, EVP, Chief R&D Officer | Open Market Sale | -6,326 | 60.38 | -381,937.31 | -61,6% | |
| 2026-02-26 | Davis George Eric | Officer, EVP, Chief Legal Officer | Open Market Sale | -26,061 | 61.36 | -1,599,102.96 | -257,8% | |
| 2025-05-20 | Burkhart Erin | Officer, GVP, Chief Accounting Officer | Open Market Sale | -1,786 | 59.31 | -105,927.66 | -17,1% | |
| 2025-05-02 | Hubbard Cristin | Officer, EVP, Chief Commercial Officer | Open Market Sale | -273 | 64.92 | -17,723.16 | -2,9% |
Fail-to-Deliver (6 Monate)
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-03-31 | 65.600 | 54,79 | 3.594.224 |
| 2026-03-25 | 114 | 54,09 | 6.166 |
| 2026-03-24 | 176 | 54,78 | 9.641 |
| 2026-03-23 | 157 | 54,13 | 8.498 |
| 2026-03-17 | 119 | 57,43 | 6.834 |
| 2026-03-10 | 120 | 60,88 | 7.306 |
| 2026-03-05 | 82 | 60,43 | 4.955 |
| 2026-03-03 | 298 | 59,74 | 17.803 |
| 2026-02-25 | 100 | 62,62 | 6.262 |
| 2026-02-20 | 1.375 | 63,42 | 87.203 |
Top-Fondshalter
Stand: 31.03.2026
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| WASHINGTON CAPITAL MANAGEMENT, INC | 10,150 | 573,374 | 100.00 |